Highest-materiality recent filing
Board fixed 1-for-10 reverse split ratio; effective 12:01 a.m. ET on May 21, 2026.
Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.
Onconetix shareholders approve reverse stock split up to 1-for-10
Reverse split proposal approved with 1,301,918 for, 253,378 against, 1,393 abstentions.
Onconetix board: Oakley and Meier resign; Dorf named Chairman; Epstein elected director
Andrew Oakley and Thomas Meier resigned from the Board effective April 20, 2026, with no disagreement with management.
Onconetix implements 1-for-5 reverse stock split to maintain Nasdaq compliance
Reverse stock split effective March 25, 2026 at 12:01 a.m. Eastern Time.
Onconetix appoints David White CEO, Sammy Dorf to board; Ramdeen resigns
David White appointed CEO effective March 18, 2026; monthly base salary of $21,700.
Onconetix appoints David White CEO, adds Sammy Dorf to board
David White appointed CEO effective March 18, 2026; monthly salary $21,700 under employment agreement.
Onconetix to acquire Realbotix in reverse merger; Realbotix holders to own 75-90%
Onconetix issues shares to Realbotix seller such that seller owns 75%–90% of fully diluted shares based on Net Cash at closing.
Onconetix shareholders approve reverse stock split (1:2 to 1:50) at special meeting
Reverse stock split proposal passed with 562,803 votes for, 123,144 against, 986 abstentions.
Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix
Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).
Onconetix boosts interim CEO pay; shareholders OK PIPE issuance for up to 12.8M shares
Interim CEO Karina Fedasz receives $45,000 bonus for 2025, payable Jan 2026; base comp increased $5,000/month from Jan 1, 2026.
Onconetix fixes 2025 annual meeting for Dec 5; shareholder submissions due Nov 10
Annual meeting set for Dec 5, 2025 at 10:00 a.m. ET at Ellenoff Grossman & Schole LLP, New York.
Onconetix secures $6.25M through PIPE of Series E convertible preferred and warrants
Sold 7,813 shares of Series E convertible preferred stock at $1,000 stated value per share.
Onconetix raises $12.9M via Series D convertible preferred stock and warrants in PIPE financing
Company sold 16,099 shares of Series D convertible preferred stock and warrants to purchase 4,362,827 shares of common stock to eleven institutional investors.
Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia
Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.
Onconetix issues $117.6K in promissory notes; amends Veru note to $5.2M, extended to Sept 19
Issued $58,823.53 principal note to Keystone Capital and $58,823.53 to KCP Fund I, each with $8,823.53 OID, netting $100K total.
Onconetix issues $118K Keystone note, extends Veru note to Aug 14, 2025; director resigns
Issued $117,647 promissory note to Keystone Capital with $17,647 OID, due March 6, 2026 or upon ELOC proceeds.
Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company
Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.
Onconetix granted Nasdaq continued listing; completes reverse stock split to meet bid price rule
Nasdaq Hearings Panel granted continued listing on June 11, 2025, subject to compliance by June 30, 2025.
Onconetix announces 1-for-85 reverse stock split effective June 13 to regain Nasdaq compliance
Reverse split 1-for-85 effective June 13, 2025; outstanding shares reduced from ~44.4M to ~521,863.
Onconetix shareholders approve reverse stock split ratio range 1:10 to 1:150
Reverse stock split proposal approved: 11,956,279 For, 4,222,940 Against, 153,929 Abstentions.
Onconetix receives second Nasdaq delisting notice for late 10-Q; hearing set May 27
Received Nasdaq deficiency notice May 20 for failure to timely file Q1 2025 10-Q, adding to existing non-compliance for late 10-K.
Onconetix receives additional Nasdaq delisting notice for late 10-K; hearing set for May 27
Received April 24, 2025 notice for failing to file FY2024 10-K, violating Listing Rule 5250(c)(1).
Onconetix faces Nasdaq delisting; stock at $0.10 or less for 10 days, hearing requested
Nasdaq notified Onconetix on April 14, 2025, that its stock had closing bid of $0.10 or less for ten consecutive trading days.
Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%
Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.
Executive Chairman Sapirstein resigns; Interim CFO Fedasz appointed Interim CEO
James Sapirstein resigned as Executive Chairman and Board member, effective March 28, 2025.
Onconetix presents Proclarix data at EAU; 96% sensitivity, 22% biopsy avoidance in Danish cohort
Proclarix evaluated in 808 patients; in targeted subpopulation (n=371), negative test gave 5% csPCa probability vs 14% for %fPSA (p=0.028).
Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients
Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).
Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns
Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.
Onconetix issues $117k promissory note, changes auditor, strategy officer resigns
Entered $117,647 promissory note with Keystone Capital; purchase price $100k, due Nov 12, 2025 or earlier from ELOC proceeds.
Onconetix receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq notice based on closing bid price below $1.00 from Nov 25, 2024 to Jan 10, 2025.
Onconetix settles IQVIA dispute for $150k, records $0.9M reduction in accounts payable
Resolved IQVIA dispute with $150k payment, avoiding claimed $1.09M liability.
Onconetix receives Nasdaq deficiency notice for late Q3 filing; resolved by filing on Dec 10
Received Nasdaq notice on Dec 6, 2024 for failure to timely file Form 10-Q for Q3 2024.
Onconetix obtains waiver of October payment to Veru; future payment percentage rises to 25%
Waives Oct 2024 cash receipt payment due Nov 20, 2024 until Onconetix receives at least $97,000 from Keystone equity line.
Onconetix auditor EisnerAmper resigns; material weaknesses persist
EisnerAmper LLP resigned as auditor on Oct 15, 2024, effective upon filing of Q3 2024 10-Q.
Onconetix resolves Nasdaq delisting risk via reverse split & listing approval
Received delisting notice on Sep 18 for bid price & equity non-compliance; Nasdaq approved initial listing on Sep 19, rendering issues moot.
Onconetix closes $2.0M PIPE and $25M ELOC for working capital
Sold 3,499 Series C preferred shares (stated value $1,000) at $4.5056 conversion price; warrants for 591,856 shares at $4.38.
Reverse stock split at ratio 1:40 effective Sept. 24, 2024; no fractional shares issued, cash paid in lieu.
Onconetix announces 1-for-40 reverse stock split effective Sept 24, 2024 to regain Nasdaq compliance
Reverse stock split at 1:40 ratio; outstanding shares reduced from ~30.2M to ~755,000 shares.
Amended forbearance extends April 2024 Note forbearance to March 31, 2025; extends September 2024 Note maturity to June 30, 2025.
Onconetix shareholders elect directors and approve reverse stock split, equity plan amendments
Timothy Ramdeen and Ajit Singh were elected as Class III directors with 6,238,121 and 6,368,501 votes for, respectively.
Onconetix shareholders to vote on Series B conversion, $5M financing at Sept 5 meeting
Annual meeting on Sept 5, 2024; vote on conversion of 269.7M shares from Series B Preferred and $5M PMX private placement.
Nasdaq ruled Proteomedix AG acquisition triggers Change of Control; must satisfy initial listing rules including $4.00 minimum bid price.
Annual meeting scheduled for September 5, 2024 at 10:00 AM ET in New York City.
Onconetix closes warrant exercise for $1.11M gross; issues new warrants for 22.4M shares
Gross proceeds of $1.11M from exercise of 7,458,642 existing warrants at reduced $0.15/share.
Onconetix raises $1.1M via warrant exercise inducement; issues 22.4M new warrants at $0.15
Existing warrants for 7,458,642 shares exercised at reduced price of $0.15 (original $1.09-$2.546).
Onconetix appoints Karina Fedasz as Interim CFO at $15k/month plus $2.5k signatory fee
Appointment effective June 10, 2024; consulting agreement term of one year, 30-day termination notice.
Onconetix CFO Bruce Harmon resigns; Karina Fedasz appointed interim CFO
Bruce Harmon resigned as CFO effective June 8, 2024; receives $66,152.61 severance under release agreement.
Stockholders' equity was $1,404,476 for FY2023, below Nasdaq's $2.5M minimum requirement.
Onconetix enters forbearance on $10M note; pauses ENTADFI commercialization
Forbearance with Veru extends April 2024 note maturity to March 31, 2025; interest at 10% on unpaid balance.
On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.
Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).
On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director
On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.
On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately
On February 18, 2025, Christian Brühlmann resigned from his position as Chief Strategy Officer of the Company.
In connection with Ms. Fedasz’s appointment as Interim Chief Financial Officer, on June 10, 2024, the Company and Ms. Fedasz entered into a consulting agreement (the “ Fedasz Consulting Agreement ”), pursuant to which Ms. Fedasz will serve as Interim Chief Financial Officer of the Company and will be paid $15,000 per month for up to 80 hours of monthly service to the Company and will provide signatory services for $2,500 per month.
On June 10, 2024, the Company appointed Karina M. Fedasz, 51, as Interim Chief Financial Officer of the Company, effective immediately.
On June 8, 2024, Bruce Harmon resigned as Chief Financial Officer of Onconetix, Inc. (the “ Company ”), effective immediately.
On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.
On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.
On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).
Max materiality 0.90 · Median 0.65 · Most common event other_material